Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Volume

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on May 10, 2023 12:06pm

212 Views

Post# 35440900

RE:Volume

Venture,

I agree with you that we will have to wait for a significant event that signals that management has delivered the goods before the price wil appreciate significantly. But that puts us all in a bind, because we need the price to go up to do a sensible deal.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China